Compare VSME & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSME | ALZN |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.5M |
| IPO Year | 2022 | 2021 |
| Metric | VSME | ALZN |
|---|---|---|
| Price | $1.05 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 100.3K | 31.3K |
| Earning Date | 04-30-2026 | 12-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.84 |
| 52 Week High | $5.38 | $2.61 |
| Indicator | VSME | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 37.84 |
| Support Level | $1.05 | $1.20 |
| Resistance Level | $1.16 | $1.25 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 97.86 | 33.36 |
VS Media Holdings Ltd manages a network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fan bases on social media platforms. The company's business provides value to two business stakeholders: marketing services and social commerce. The firm generates almost all of its revenue from marketing services, which reflects the company's business of marketing services to clients and social media platforms. The social commerce segment reflects the company's business of social commerce with customers. Geographically, the firm generates revenue from the HK SAR and Taiwan.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.